Jump to navigation
Dr. Capeding led the first Phase 3 trial ever completed for a dengue vaccine candidate. The results of this trial in Asia (involving Sanofi Pasteur’s dengue vaccine candidate) were published this summer, July 11, in The Lancet.
Sabin Vaccine Institute President Dr. Peter Hotez is leading the research at Texas Children’s Hospital and Baylor College of Medicine to develop the first-ever vaccine for Chagas disease.
"It was safer. It was more effective, conferring immunity that might last a lifetime.
Since late 2008, the Sustainable Immunization Financing (SIF) Program has been operating in twelve African, and three Asian pilot countries.
Dr. Peter Hotez, president of the Sabin Vaccine Institute, was honored last week with the prestigious Abraham Horwitz Award for Excellence in Inter-American Public Health.